MedTrace Logo

French Study in Real Life Evaluating Xybilun

NCT04114240 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2019-10-04

No results posted yet for this study

Summary

Collecting Xybilun (Viagra's generic) efficacity, tolerance, convenience and patients/doctors satisfaction's data at different doses (50-75-100 mg), is the aim of the study.

Conditions

Interventions

DRUG

Xybilun

Erectil dysfunction, Viagra generic (sildénafil)

Sponsors & Collaborators

  • Laboratoires Genévrier

    lead INDUSTRY

Principal Investigators

  • DROUPY SD Stéphane, Urologist · CHU Nîmes

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-23
Primary Completion
2019-04-26
Completion
2019-04-26

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04114240 on ClinicalTrials.gov